Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Stock data | 2023 | Change |
---|---|---|
Price | $10.17 | N/A |
Market Cap | $592.03M | N/A |
Shares Outstanding | 58.21M | 11.49% |
Employees | 284.00 | N/A |
Shareholder Equity | 555.29M | 35.03% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | -3.40 | N/A |
P/B Ratio | 1.07 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | -0.3139 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $0 | N/A |
Earnings | -$174.28M | N/A |
EPS | -2.99 | N/A |
Earnings Yield | -0.294 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $646.59M | N/A |
Total Debt | $60.76M | N/A |
Cash on Hand | $583.39M | N/A |
Debt to Equity | 0.1644 | 35.33% |
Cash to Debt | $9.60 | -20.31% |
Current Ratio | $17.52 | -9.99% |